JMD IDT. Quality Oligos. Every Time.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baudhuin, L. M.
Right arrow Articles by Thibodeau, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baudhuin, L. M.
Right arrow Articles by Thibodeau, S. N.
JMD 2005, Vol. 7, No. 2
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Analysis of hMLH1 and hMSH2 Gene Dosage Alterations in Hereditary Nonpolyposis Colorectal Cancer Patients by Novel Methods

Linnea M. Baudhuin, Ming Mai, Amy J. French, Kent E. Kruckeberg, Russell L. Swanson, Jennifer L. Winters, Laura K. Courteau and Stephen N. Thibodeau

From the Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota

A significant fraction of hereditary nonpolyposis colorectal cancer cases with defective mismatch repair (ie, Lynch syndrome) have large genomic deletions or duplications in the mismatch repair genes, hMLH1 and hMSH2, which can be challenging to detect by traditional methods. For this study, we developed and validated a novel Southern blot analysis method that allows for ascertainment of the extent of the dosage alterations on an exon-by-exon basis and compared this method to a second novel technique, multiplex ligation-dependent probe amplification (MLPA). From a total of 254 patients referred for Lynch syndrome testing, 20 of the 118 MLH1 cases and 42 of the 136 MSH2 cases had large genomic alterations, as detected by Southern blot. MLPA and Southern blot results were concordant with the exception of three major discrepancies: one because of a lack of MLPA probes for the region altered, another because of a point mutation near the MLPA probe ligation site, and another that was unexplained. Compared to Southern blot, MLPA has a shorter turn-around time, the analysis is less costly, less time-consuming, and less labor-intensive, and results are generally clear and unambiguous. However, concerns with MLPA include the presence of false-negatives and -positives because of positioning of probes and DNA variants near the probe ligation site. Overall, both Southern blot and MLPA provide important tools for the complete evaluation of patients with Lynch syndrome.




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
L. Baglietto, N. M. Lindor, J. G. Dowty, D. M. White, A. Wagner, E. B. Gomez Garcia, A. H. J. T. Vriends, Dutch Lynch Syndrome Study Group, N. R. Cartwright, R. A. Barnetson, et al.
Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers
J Natl Cancer Inst, February 3, 2010; 102(3): 193 - 201.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
C. P. Vaughn, E. Lyon, and W. S. Samowitz
Confirmation of Single Exon Deletions in MLH1 and MSH2 Using Quantitative Polymerase Chain Reaction
J. Mol. Diagn., July 1, 2008; 10(4): 355 - 360.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Warshawsky, O. B. Chernova, C. A. Hubner, R. Stindl, M. Henneke, A. Gal, and M. R. Natowicz
Multiplex Ligation-Dependent Probe Amplification for Rapid Detection of Proteolipid Protein 1 Gene Duplications and Deletions in Affected Males and Carrier Females with Pelizaeus-Merzbacher Disease
Clin. Chem., July 1, 2006; 52(7): 1267 - 1275.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology and the Association for Molecular Pathology.